JP2020513018A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513018A5
JP2020513018A5 JP2019554870A JP2019554870A JP2020513018A5 JP 2020513018 A5 JP2020513018 A5 JP 2020513018A5 JP 2019554870 A JP2019554870 A JP 2019554870A JP 2019554870 A JP2019554870 A JP 2019554870A JP 2020513018 A5 JP2020513018 A5 JP 2020513018A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
use according
pharmaceutically active
active dose
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026080 external-priority patent/WO2018187467A1/en
Publication of JP2020513018A publication Critical patent/JP2020513018A/ja
Publication of JP2020513018A5 publication Critical patent/JP2020513018A5/ja
Pending legal-status Critical Current

Links

JP2019554870A 2017-04-05 2018-04-04 パーキンソン病(pd)および関連する障害を治療するための組成物および方法 Pending JP2020513018A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482162P 2017-04-05 2017-04-05
US62/482,162 2017-04-05
US201762511740P 2017-05-26 2017-05-26
US62/511,740 2017-05-26
PCT/US2018/026080 WO2018187467A1 (en) 2017-04-05 2018-04-04 Compositions and methods for treating parkinson's disease (pd) and related disorders

Publications (2)

Publication Number Publication Date
JP2020513018A JP2020513018A (ja) 2020-04-30
JP2020513018A5 true JP2020513018A5 (https=) 2021-05-13

Family

ID=62063615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554870A Pending JP2020513018A (ja) 2017-04-05 2018-04-04 パーキンソン病(pd)および関連する障害を治療するための組成物および方法

Country Status (7)

Country Link
US (1) US11433102B2 (https=)
EP (1) EP3606541A1 (https=)
JP (1) JP2020513018A (https=)
CN (1) CN110831606A (https=)
AU (1) AU2018250206A1 (https=)
CA (1) CA3058818A1 (https=)
WO (1) WO2018187467A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
EP4098268A1 (en) 2021-06-01 2022-12-07 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing lyophilized fecal matter filtrate
CN113559129B (zh) * 2021-08-18 2023-07-28 唐颐控股(深圳)有限公司 通过细菌治疗帕金森病的纳米装甲防护单细胞制品及其制备方法
EP4525897A1 (en) * 2022-05-20 2025-03-26 Institut Pasteur Lachnospiraceae spp and ruminococcus lactaris strains for the treatment and prevention of alzheimer's disease and aging
US20240033217A1 (en) 2022-08-01 2024-02-01 Novel Biome Solutions Inc. Method of orally administering a fecal microbiota transplant composition

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (https=) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (https=) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (https=) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
NZ287420A (en) 1994-05-26 1997-12-19 Bracco Spa Lactobacillus strains with enhanced gut adhesion
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998013068A1 (fr) 1996-09-26 1998-04-02 Vladimir Borisovich Kuperman Medicament prophylactique 'trisan'
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
CN1300318A (zh) 1998-05-06 2001-06-20 中村启次郎 含有性质不同且彼此共生的微生物和其代谢物的微生物培养物,含有该培养物活性组分的载体和吸附剂及其用途
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
AU6049599A (en) 1998-09-17 2000-04-03 Baxter Healthcare Sa Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7763276B1 (en) 1999-02-26 2010-07-27 Shionogi & Co., Ltd. Chewable soft capsules having improved administration properties and process for producing the same
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
EP1303285A2 (en) 2000-07-17 2003-04-23 Chr. Hansen A/S Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
AU2002305758B2 (en) 2001-06-01 2006-09-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2003004003A1 (fr) 2001-07-05 2003-01-16 Wakunaga Pharmaceutical Co., Ltd. Capsules molles
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
KR20060073937A (ko) 2003-08-18 2006-06-29 더 바이오 밸런스 코포레이션 안정한 액상 촉생제 조성물, 그의 제조 및 응용
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
WO2006013588A1 (en) 2004-08-05 2006-02-09 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
ATE367821T1 (de) 2004-08-05 2007-08-15 Anidral Srl Folsäure produzierende bifidobacterium bakterienstämme, ihre formulierungen und verwendung
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
WO2006127355A2 (en) 2005-05-20 2006-11-30 Dow Global Technologies Inc. Oral drug compliance monitoring using radio frequency identification tags
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
SI2136825T1 (sl) 2007-03-01 2014-04-30 Probi Ab Uporaba lactobacillus plantarium za povečanje bakterijske raznolikosti
BRPI0809448A2 (pt) 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
EP2134833B1 (en) 2007-03-28 2016-03-09 Alimentary Health Limited Probiotic bifidobacterium strain
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP2010529073A (ja) 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
MX2009013063A (es) 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
EP2264042B1 (en) 2007-07-27 2012-07-18 Cargill, Incorporated Micronization of polyols
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2183318B1 (en) 2007-08-31 2012-03-07 Invista Technologies S.A R.L. Oxygen scavenging plastic compositions
US20100233278A1 (en) 2007-09-27 2010-09-16 Akiko Ookawa Rapidly disintegrating solid preparation
EP2205213A2 (en) 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
CA2702935A1 (en) 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US8658153B2 (en) 2007-10-20 2014-02-25 Universite De Liege Bifidobacterial species
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
US9314454B2 (en) 2007-12-28 2016-04-19 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
CN101496819A (zh) 2008-01-31 2009-08-05 青岛东海药业有限公司 真杆菌、梭菌制剂及其应用
KR100913405B1 (ko) 2008-03-25 2009-08-21 광주과학기술원 Th2-매개 면역 질환의 예방 또는 치료용 조성물
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
CA2760248C (en) 2009-04-30 2019-05-28 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
ES2610829T3 (es) 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
CA2792647A1 (en) 2010-03-10 2011-09-15 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
EP2646567A4 (en) 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE FOR THE DIAGNOSIS OF GASTROINTESTINAL CARCINOMA
CA2813606C (en) 2010-10-07 2019-01-22 Sarkis K. Mazmanian Probiotic therapies for autism
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
CN103857402A (zh) 2011-10-11 2014-06-11 阿基姆医药公司 包括厌氧培养的人类肠道微生物群的组合物
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
CA2872149C (en) 2012-05-02 2019-03-19 Charles River Laboratories, Inc. Viability staining method
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
BR112015009975A2 (pt) 2012-11-01 2017-07-11 Academisch Ziekenhuis Groningen métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2922555A4 (en) 2012-11-26 2016-06-15 Borody Thomas J COMPOSITIONS FOR THE RESTORATION OF A FÄKALBIOZÖNOSE AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014176632A1 (en) 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) * 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3107553B1 (en) 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
JP6357222B2 (ja) 2014-03-28 2018-07-11 株式会社ヤクルト本社 酪酸産生菌及びその利用
US20160199425A1 (en) * 2015-01-08 2016-07-14 Nubiome, Inc. Treatment and Prophylaxis for Parkinson's Disease
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
BR112017024264B1 (pt) * 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
MX2018005107A (es) * 2015-10-26 2018-08-09 Crestovo Holdings Llc Composiciones y metodos para la terapia relacionada con la microbiota fecal.
CN115887508A (zh) 2016-03-04 2023-04-04 加利福尼亚大学董事会 微生物聚生体及其用途
WO2017210428A1 (en) 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Similar Documents

Publication Publication Date Title
JP2020513018A5 (https=)
Henn et al. A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
JP2019520340A5 (https=)
JP2019525944A5 (https=)
KR102358879B1 (ko) 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
KR101774721B1 (ko) 수면을 돕기 위한 조성물 및 방법
RU2018118651A (ru) Композиции и способы терапии, связанной с фекальной микробиотой
US11433102B2 (en) Compositions and methods for treating Parkinson's disease (PD) and related disorders
Sharma et al. Management of overt hepatic encephalopathy
US11801275B2 (en) Compositions and methods for common colds
HRP20140657T1 (hr) Laminin-1 za primjenu radi pojaäśanja regeneracije mišiä†a nakon ozljede ili za bolje zacjeljivanje rana ako se daje sistemski
Danesh et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis
JP2016505050A5 (https=)
WO2023192161A3 (en) Methods and compositions for attenuating immune response associated with rna therapeutics
Lee et al. A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
ES2057021T3 (es) Un metodo de manufactura de una dosificacion farmaceutica solida en forma de triturado en tableta.
US20220280585A1 (en) Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof
Ugarte et al. Comparison of the efficacy and safety of sildenafil citrate (Viagra®) and oral phentolamine for the treatment of erectile dysfunction
Madisch et al. Benefit of a herbal preparation in patients with irritable bowel syndrome: Results of a double-blind, randomized, placebo-controlled multicenter trial
CN104000809A (zh) 一种防治冠心病心绞痛的药物组合物及其应用
Colley et al. Novel bilayer mucoadhesive patches for delivery of clobetasol-17-propionate to the oral mucosa to treat oral lichen planus; an in vitro and in vivo evaluation
RU2022100109A (ru) Новая пробиотическая композиция для регулирования кишечного иммунитета
Emmanuel et al. Prucalopride (PRU) improves colonic transit and stool frequency in patients (PTS) with slow and normal transit constipation
Rich et al. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?